Brought to you by 
The Medicines Co. licenses Immunotech 5-HTagonist
29 Mar 2011
Executive Summary
The Medicines Co. (inlicenses late stage drugs) has acquired exclusive worldwide rights to IS-159, a selective 5-HT receptor agonist, for the treatment of acute migraine headache from Beckman Coulter division Immunotech SA.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
The Medicines Co. licenses Immunotech 5-HTagonist
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice